Veru (VERU) Non Operating Interest Expenses (2014 - 2024)
Veru's (VERU) quarterly Non Operating Interest Expenses came in at $169867.0 in Q3 2024, down 18.02% year-over-year from $207201.0 in Q4 2023, and up 33.4% quarter-over-quarter from $127336.0 in Q2 2024.
Analysis
Veru (VERU) Non Operating Interest Expenses (2014 - 2024) Analysis & Trends
Veru (VERU) has reported Non Operating Interest Expenses for 9 consecutive years, with $169867.0 the latest figure, recorded in Q3 2024.
- On a quarterly basis, Non Operating Interest Expenses fell 18.02% year-over-year to $169867.0 in Q3 2024; TTM through Sep 2024 was $607470.0, a 74.97% decrease from a year earlier, with the FY2024 full-year figure at $607470.0, down 74.97% from the prior year.
- Non Operating Interest Expenses was $169867.0 for Q3 2024 at Veru, up from $127336.0 in the prior quarter.
- Over five years, Non Operating Interest Expenses peaked at $1.3 million in Q2 2021 and troughed at $127336.0 in Q2 2024.
- A 5-year average of $829966.3 and a median of $1.1 million in 2020 frame the typical range for Non Operating Interest Expenses.
- Across the five-year window, Non Operating Interest Expenses advanced 10.07% in 2021 and sank 81.11% in 2023, its largest moves.
- Over 5 years, Non Operating Interest Expenses stood at $1.2 million in 2020, then fell by 2.56% to $1.2 million in 2021, then declined by 24.64% to $873230.0 in 2022, then slumped by 81.11% to $164957.0 in 2023, then advanced by 2.98% to $169867.0 in 2024.
- The last three Non Operating Interest Expenses figures came in at $169867.0 (Q3 2024), $127336.0 (Q2 2024), and $145310.0 (Q1 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 2.90 Mn |
| 10 | Veru | 57.86 Mn | 32.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 169,867.00 |
| Jun 30, 2024 | 127,336.00 |
| Mar 31, 2024 | 145,310.00 |
| Dec 31, 2023 | 164,957.00 |
| Sep 30, 2023 | 207,201.00 |
| Jun 30, 2023 | 648,917.00 |
| Mar 31, 2023 | 697,693.00 |
| Dec 31, 2022 | 873,230.00 |
| Sep 30, 2022 | 812,321.00 |
| Jun 30, 2022 | 1.19 Mn |
| Mar 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 1.16 Mn |
| Sep 30, 2021 | 1.16 Mn |
| Jun 30, 2021 | 1.29 Mn |
| Mar 31, 2021 | 1.25 Mn |
| Dec 31, 2020 | 1.19 Mn |
| Sep 30, 2020 | 1.15 Mn |
| Jun 30, 2020 | 1.17 Mn |
| Mar 31, 2020 | 1.16 Mn |
| Dec 31, 2019 | 1.14 Mn |